Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Theravance Biopharma, Inc.'s quarterly P/E stands at 52.1x.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -15.87 | 52.14 | 2.55 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 14.36 | 9.48 | 5.34 | 7.21 | 6.18 | 5.86 | 7.25 | 7.47 | 7.91 | 7.20 | 10.67 | 16.39 | 12.90 |
| — | +61.8% | -26.3% | -3.4% | -21.8% | -18.6% | -32.0% | -54.4% | -38.7% | -53.2% | -31.8% | +20.2% | -5.6% | |
| P/B Ratio | 5.08 | 3.26 | 2.49 | 2.67 | 2.64 | 2.13 | 2.13 | 2.11 | 2.61 | 1.84 | 2.09 | 1.84 | 1.71 |
| — | +53.0% | +16.6% | +26.5% | +1.4% | +16.0% | +1.9% | +14.7% | +52.4% | +15.2% | — | — | — | |
| P/FCF | — | — | 0.67 | 2.58 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Theravance Biopharma, Inc.'s operating margin was -32.3% in Q3 2025, down 21.9 pp QoQ and up 32.0 pp YoY. The trailing four-quarter average of -46.4% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 31.9% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 59.4% | 60.0% | 25.6% | 100.0% | 45.1% | 30.2% | 38.2% | 52.7% | 91.5% | 31.4% | -39.9% | -4.8% |
| — | +31.9% | +98.7% | -33.0% | +89.9% | -50.7% | -4.0% | +195.7% | +1203.9% | +340.7% | +189.7% | +47.7% | +95.6% | |
| Operating Margin | -72.9% | -32.3% | -10.4% | -93.8% | -49.1% | -64.2% | -110.2% | -77.3% | -35.5% | -55.8% | -117.3% | -239.1% | -119.0% |
| — | +49.7% | +90.6% | -21.4% | -38.1% | -15.1% | +6.1% | +67.7% | +70.1% | +51.1% | +43.9% | +15.2% | +68.3% | |
| Net Margin | -87.6% | 18.1% | 209.3% | -88.2% | -82.8% | -75.3% | -115.9% | -80.4% | -48.4% | -57.0% | -113.8% | -212.0% | -70.7% |
| — | +124.0% | +280.5% | -9.7% | -70.9% | -32.0% | -1.9% | +62.1% | +31.5% | -100.8% | -53.5% | -7.8% | +67.0% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -29.0% | 1.6% | 28.1% | -8.0% | -8.6% | -6.7% | -8.3% | -5.6% | -3.7% | -3.4% | -4.8% | -5.4% | -2.2% |
| — | +123.6% | +438.3% | -42.4% | -131.9% | -96.8% | -72.5% | -2.7% | -65.0% | -100.2% | — | — | — | |
| ROA | -15.3% | 0.9% | 14.2% | -3.9% | -4.4% | -3.5% | -4.5% | -3.1% | -2.1% | -2.1% | -3.2% | -3.9% | -1.5% |
| — | +124.3% | +416.1% | -25.7% | -104.4% | -69.9% | -41.9% | +19.7% | -41.5% | -101.3% | -38.8% | +45.8% | +81.6% | |
| ROIC | -17.2% | -10.5% | -4.4% | -7.4% | -3.5% | -4.1% | -6.0% | -4.0% | -2.1% | -2.9% | -5.3% | -8.7% | -8.4% |
| — | -160.1% | +26.6% | -86.5% | -67.3% | -39.2% | -14.1% | +54.1% | +75.2% | +51.5% | +29.0% | +27.1% | +53.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 90.8% YoY to 9.48x, strengthening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.28 | 0.19 | 0.21 | 0.29 | 0.28 | 0.24 | 0.24 | 0.23 | 0.23 | 0.21 | 0.18 | 0.14 | 0.12 |
| — | -20.9% | -14.2% | +24.1% | +23.0% | +17.3% | +30.6% | +69.3% | +95.5% | +90.6% | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.02 | 9.48 | 6.70 | 4.77 | 5.02 | 4.97 | 5.20 | 5.74 | 5.39 | 6.37 | 7.82 | 9.98 | 12.31 |
| — | +90.8% | +28.9% | -16.9% | -6.9% | -22.0% | -33.5% | -42.5% | -56.2% | +77.0% | +64.9% | +115.6% | +188.6% | |
| Quick Ratio | 5.02 | 9.48 | 6.70 | 4.77 | 5.02 | 4.97 | 5.20 | 5.74 | 5.39 | 6.37 | 7.82 | 9.98 | 12.31 |
| — | +90.8% | +28.9% | -16.9% | -6.9% | -22.0% | -33.5% | -42.5% | -56.2% | +77.0% | +64.9% | +115.6% | +188.6% | |
| Interest Coverage | -18.44 | -11.27 | -4.11 | -22.45 | -14.31 | -17.20 | -24.39 | -17.82 | -10.02 | -14.38 | -28.39 | -45.29 | -31.64 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonTheravance Biopharma, Inc.'s current P/E is -15.9x. The average P/E over the last 2 quarters is 27.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Theravance Biopharma, Inc.'s current operating margin is -72.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Theravance Biopharma, Inc.'s business trajectory between earnings reports.